{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:21:34Z","timestamp":1789528894367,"version":"build-2803163510"},"reference-count":242,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T00:00:00Z","timestamp":1496793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T00:00:00Z","timestamp":1496793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL116042"],"award-info":[{"award-number":["R01HL116042"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL112597"],"award-info":[{"award-number":["R01HL112597"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL120659"],"award-info":[{"award-number":["R01HL120659"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s11010-017-3092-z","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T13:35:49Z","timestamp":1496842549000},"page":"13-36","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma"],"prefix":"10.1007","volume":"437","author":[{"given":"Vikrant","family":"Rai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Abdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah N.","family":"Alsuwaidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-0013","authenticated-orcid":false,"given":"Devendra K.","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,7]]},"reference":[{"issue":"24","key":"3092_CR1","doi-asserted-by":"publisher","first-page":"6678","DOI":"10.1158\/1078-0432.CCR-13-1721","volume":"19","author":"TF Greten","year":"2013","unstructured":"Greten TF, Duffy AG, Korangy F (2013) Hepatocellular carcinoma from an immunologic perspective. Clin Cancer Res 19(24):6678\u20136685","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"3092_CR2","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1111\/j.1872-034X.2007.00168.x","volume":"37","author":"HB El-Serag","year":"2007","unstructured":"El-Serag HB (2007) Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 37(Suppl 2):S88\u2013S94","journal-title":"Hepatol Res"},{"issue":"7","key":"3092_CR3","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","volume":"132","author":"HB El-Serag","year":"2007","unstructured":"El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7):2557\u20132576","journal-title":"Gastroenterology"},{"issue":"24","key":"3092_CR4","doi-asserted-by":"publisher","first-page":"7696","DOI":"10.3748\/wjg.v20.i24.7696","volume":"20","author":"Z Zeng","year":"2014","unstructured":"Zeng Z (2014) Human genes involved in hepatitis B virus infection. World J Gastroenterol 20(24):7696\u20137706","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3092_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1046\/j.1365-2893.1999.6120139.x","volume":"6","author":"AR Zanetti","year":"1999","unstructured":"Zanetti AR (1999) Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6(1):35\u201347","journal-title":"J Viral Hepat"},{"issue":"2","key":"3092_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/ijc.1440","volume":"94","author":"DM Parkin","year":"2001","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94(2):153\u2013156","journal-title":"Int J Cancer"},{"issue":"3\u20134","key":"3092_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1159\/000343837","volume":"1","author":"AG Miamen","year":"2012","unstructured":"Miamen AG, Dong H, Roberts LR (2012) Immunotherapeutic approaches to hepatocellular carcinoma treatment. Liver Cancer 1(3\u20134):226\u2013237","journal-title":"Liver Cancer"},{"issue":"4","key":"3092_CR8","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/hep.24149","volume":"53","author":"E Mizukoshi","year":"2011","unstructured":"Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Sakai A, Sakai Y et al (2011) Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology 53(4):1206\u20131216","journal-title":"Hepatology"},{"issue":"13","key":"3092_CR9","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.1158\/1078-0432.CCR-04-0181","volume":"10","author":"F Korangy","year":"2004","unstructured":"Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP et al (2004) Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 10(13):4332\u20134341","journal-title":"Clin Cancer Res"},{"issue":"5844","key":"3092_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/bmj.1.5844.16","volume":"1","author":"A Primack","year":"1973","unstructured":"Primack A, Vogel CL, Barker LF (1973) Immunological studies in Ugandan patients with hepatocellular carcinoma. BMJ 1(5844):16\u201319","journal-title":"BMJ"},{"issue":"2","key":"3092_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1006\/clim.2002.5245","volume":"104","author":"S Beckebaum","year":"2002","unstructured":"Beckebaum S, Cicinnati VR, Dworacki G, Muller-Berghaus J, Stolz D, Harnaha J et al (2002) Reduction in the circulating pDC1\/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol 104(2):138\u2013150","journal-title":"Clin Immunol"},{"issue":"2","key":"3092_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0168-8278(99)80231-1","volume":"31","author":"T Ninomiya","year":"1999","unstructured":"Ninomiya T, Akbar SM, Masumoto T, Horiike N, Onji M (1999) Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol 31(2):323\u2013331","journal-title":"J Hepatol"},{"issue":"6","key":"3092_CR13","doi-asserted-by":"publisher","first-page":"e1008355","DOI":"10.1080\/2162402X.2015.1008355","volume":"4","author":"A Pedroza-Gonzalez","year":"2015","unstructured":"Pedroza-Gonzalez A, Zhou G, Vargas-Mendez E, Boor PP, Mancham S, Verhoef C et al (2015) Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors. Oncoimmunology 4(6):e1008355","journal-title":"Oncoimmunology"},{"issue":"5","key":"3092_CR14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1586\/1744666X.2016.1145056","volume":"12","author":"V Rai","year":"2016","unstructured":"Rai V, Dietz NE, Agrawal DK (2016) Immunological basis for treatment of graft versus host disease after liver transplant. Expert Rev Clin Immunol 12(5):583\u2013593","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"3092_CR15","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1053\/j.gastro.2008.02.090","volume":"134","author":"HB El-Serag","year":"2008","unstructured":"El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134(6):1752\u20131763","journal-title":"Gastroenterology"},{"issue":"7","key":"3092_CR16","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/sj.bjc.6603341","volume":"95","author":"M den Brok","year":"2006","unstructured":"den Brok M, Sutmuller RPM, Nierkens S, Bennink EJ, Frielink C, Toonen LWJ et al (2006) Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer 95(7):896\u2013905","journal-title":"Br J Cancer"},{"issue":"2","key":"3092_CR17","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1158\/0008-5472.CAN-05-2244","volume":"66","author":"A Zerbini","year":"2006","unstructured":"Zerbini A, Pilli M, Penna A, Pelosi G, Schianchi C, Molinari A et al (2006) Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Can Res 66(2):1139\u20131146","journal-title":"Can Res"},{"issue":"23","key":"3092_CR18","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.3748\/wjg.v12.i23.3716","volume":"12","author":"J Hansler","year":"2006","unstructured":"Hansler J, Wissniowski TuT, Schuppan D, Witte A, Bernatik T, Hahn EG et al (2006) Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol 12(23):3716\u20133721","journal-title":"World J Gastroenterol"},{"issue":"5","key":"3092_CR19","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1053\/j.gastro.2009.12.051","volume":"138","author":"A Zerbini","year":"2010","unstructured":"Zerbini A, Pilli M, Laccabue D, Pelosi G, Molinari A, Negri E et al (2010) Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology 138(5):1931\u20131942","journal-title":"Gastroenterology"},{"issue":"4","key":"3092_CR20","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/hep.26153","volume":"57","author":"E Mizukoshi","year":"2013","unstructured":"Mizukoshi E, Yamashita T, Arai K, Sunagozaka H, Ueda T, Arihara F et al (2013) Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology 57(4):1448\u20131457","journal-title":"Hepatology"},{"issue":"3","key":"3092_CR21","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.4049\/jimmunol.178.3.1914","volume":"178","author":"L Ayaru","year":"2007","unstructured":"Ayaru L, Pereira SP, Alisa A, Pathan AA, Williams R, Davidson B et al (2007) Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J Immunol 178(3):1914\u20131922","journal-title":"J Immunol"},{"issue":"4","key":"3092_CR22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00535-009-0155-2","volume":"45","author":"K Hiroishi","year":"2008","unstructured":"Hiroishi K, Eguchi J, Baba T, Shimazaki T, Ishii S, Hiraide A et al (2008) Strong CD8+ T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol 45(4):451\u2013458","journal-title":"J Gastroenterol"},{"issue":"1","key":"3092_CR23","first-page":"63","volume":"40","author":"D Nobuoka","year":"2012","unstructured":"Nobuoka D, Motomura Y, Shirakawa H, Yoshikawa T, Kuronuma T, Takahashi M et al (2012) Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. Int J Oncol 40(1):63\u201370","journal-title":"Int J Oncol"},{"issue":"9","key":"3092_CR24","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.ultrasmedbio.2004.08.003","volume":"30","author":"F Wu","year":"2004","unstructured":"Wu F, Wang ZB, Lu P, Xu ZL, Chen WZ, Zhu H et al (2004) Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation. Ultrasound Med Biol 30(9):1217\u20131222","journal-title":"Ultrasound Med Biol"},{"issue":"9","key":"3092_CR25","doi-asserted-by":"publisher","first-page":"e23621","DOI":"10.1371\/journal.pone.0023621","volume":"6","author":"Z Zeng","year":"2011","unstructured":"Zeng Z, Shi F, Zhou L, Zhang MN, Chen Y, Chang XJ et al (2011) Upregulation of circulating PD-L1\/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS ONE 6(9):e23621","journal-title":"PLoS ONE"},{"issue":"5","key":"3092_CR26","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1158\/1078-0432.CCR-15-1352","volume":"22","author":"L Shi","year":"2016","unstructured":"Shi L, Chen L, Wu C, Zhu Y, Xu B, Zheng X et al (2016) PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. Clin Cancer Res 22(5):1173\u20131184","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3092_CR27","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jhep.2011.07.031","volume":"56","author":"U Asghar","year":"2012","unstructured":"Asghar U, Meyer T (2012) Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol 56(3):686\u2013695","journal-title":"J Hepatol"},{"issue":"4","key":"3092_CR28","first-page":"352","volume":"14","author":"G Cabibbo","year":"2010","unstructured":"Cabibbo G, Craxi A (2010) Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 14(4):352\u2013355","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"8","key":"3092_CR29","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.3390\/v2081504","volume":"2","author":"B Bartosch","year":"2010","unstructured":"Bartosch B (2010) Hepatitis B and C viruses and hepatocellular carcinoma. Viruses 2(8):1504\u20131509","journal-title":"Viruses"},{"issue":"10","key":"3092_CR30","first-page":"4531","volume":"33","author":"B Tomov","year":"2013","unstructured":"Tomov B, Popov D, Tomova R, Vladov N, Den Otter W, Krastev Z (2013) Therapeutic response of untreatable hepatocellular carcinoma after application of the immune modulators IL-2, BCG and melatonin. Anticancer Res 33(10):4531\u20134535","journal-title":"Anticancer Res"},{"issue":"11","key":"3092_CR31","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrc2256","volume":"7","author":"JA Aguirre-Ghiso","year":"2007","unstructured":"Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7(11):834\u2013846","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3092_CR32","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1007\/s11605-007-0459-6","volume":"12","author":"C Christophi","year":"2008","unstructured":"Christophi C, Harun N, Fifis T (2008) Liver regeneration and tumor stimulation-a review of cytokine and angiogenic factors. J Gastrointest Surg 12(5):966\u2013980","journal-title":"J Gastrointest Surg"},{"issue":"3","key":"3092_CR33","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s12072-010-9192-4","volume":"4","author":"JA Chen","year":"2010","unstructured":"Chen JA, Shi M, Li JQ, Qian CN (2010) Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration. Hepatol Int 4(3):537\u2013547","journal-title":"Hepatol Int"},{"issue":"5 Suppl 1","key":"3092_CR34","doi-asserted-by":"publisher","first-page":"S232","DOI":"10.1053\/j.gastro.2004.09.038","volume":"127","author":"LH Butterfield","year":"2004","unstructured":"Butterfield LH (2004) Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1):S232\u2013S241","journal-title":"Gastroenterology"},{"key":"3092_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1146\/annurev.pathol.1.110304.100230","volume":"1","author":"LG Guidotti","year":"2006","unstructured":"Guidotti LG, Chisari FV (2006) Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol Mech Dis 1:23\u201361","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"1","key":"3092_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/viro.2001.0885","volume":"284","author":"S-L Tan","year":"2001","unstructured":"Tan S-L, Katze MG (2001) How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology 284(1):1\u201312","journal-title":"Virology"},{"issue":"3","key":"3092_CR37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/BF02256065","volume":"9","author":"GR Reyes","year":"2002","unstructured":"Reyes GR (2002) The nonstructural NS5A protein of hepatitis C virus: an expanding, multifunctional role in enhancing hepatitis C virus pathogenesis. J Biomed Sci 9(3):187\u2013197","journal-title":"J Biomed Sci"},{"issue":"9","key":"3092_CR38","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1099\/vir.0.80204-0","volume":"85","author":"A Macdonald","year":"2004","unstructured":"Macdonald A, Harris M (2004) Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 85(9):2485\u20132502","journal-title":"J Gen Virol"},{"issue":"Pt 5","key":"3092_CR39","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1099\/vir.0.049676-0","volume":"94","author":"C Fournier","year":"2013","unstructured":"Fournier C, Fo Helle, Vr Descamps, Morel V, Fran\u00e7ois C, Dedeurwaerder S et al (2013) Natural selection of adaptive mutations in non-structural genes increases trans-encapsidation of hepatitis C virus replicons lacking envelope protein genes. J Gen Virol 94(Pt 5):996\u20131008","journal-title":"J Gen Virol"},{"issue":"17","key":"3092_CR40","doi-asserted-by":"publisher","first-page":"9599","DOI":"10.1073\/pnas.171311298","volume":"98","author":"G Gong","year":"2001","unstructured":"Gong G, Waris G, Tanveer R, Siddiqui A (2001) Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA 98(17):9599\u20139604","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"3092_CR41","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1128\/JVI.75.3.1401-1407.2001","volume":"75","author":"M Majumder","year":"2001","unstructured":"Majumder M, Ghosh AK, Steele R, Ray R, Ray RB (2001) Hepatitis C virus NS5A physically associates with p53 and regulates p21\/waf1 gene expression in a p53-dependent manner. J Virol 75(3):1401\u20131407","journal-title":"J Virol"},{"issue":"13","key":"3092_CR42","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.1128\/JVI.75.13.6095-6106.2001","volume":"75","author":"SJ Polyak","year":"2001","unstructured":"Polyak SJ, Khabar KSA, Paschal DM, Ezelle HJ, Duverlie G, Barber GN et al (2001) Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 75(13):6095\u20136106","journal-title":"J Virol"},{"issue":"5622","key":"3092_CR43","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1126\/science.1082604","volume":"300","author":"E Foy","year":"2003","unstructured":"Foy E, Li K, Wang C, Sumpter R, Ikeda M, Lemon SM et al (2003) Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300(5622):1145\u20131148","journal-title":"Science"},{"issue":"33","key":"3092_CR44","doi-asserted-by":"publisher","first-page":"30711","DOI":"10.1074\/jbc.M209623200","volume":"278","author":"KJ Park","year":"2003","unstructured":"Park KJ, Choi SH, Choi DH, Park JM, Yie SW, Lee SY et al (2003) Hepatitis C virus NS5A protein modulates c-Jun N-terminal kinase through interaction with tumor necrosis factor receptor-associated factor 2. J Biol Chem 278(33):30711\u201330718","journal-title":"J Biol Chem"},{"issue":"6673","key":"3092_CR45","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/32588","volume":"392","author":"J Banchereau","year":"1998","unstructured":"Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392(6673):245\u2013252","journal-title":"Nature"},{"issue":"11","key":"3092_CR46","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s005350170019","volume":"36","author":"S Homma","year":"2001","unstructured":"Homma S, Toda G, Gong J, Kufe D, Ohno T (2001) Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J Gastroenterol 36(11):764\u2013771","journal-title":"J Gastroenterol"},{"issue":"20","key":"3092_CR47","first-page":"7563","volume":"61","author":"T Tatsumi","year":"2001","unstructured":"Tatsumi T, Takehara T, Kanto T, Miyagi T, Kuzushita N, Sugimoto Y et al (2001) Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res 61(20):7563\u20137567","journal-title":"Cancer Res"},{"issue":"5","key":"3092_CR48","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1053\/jhep.2001.29003","volume":"34","author":"WC Lee","year":"2001","unstructured":"Lee WC, Wang HC, Jeng LB, Chiang YJ, Lia CR, Huang PF et al (2001) Effective treatment of small murine hepatocellular carcinoma by dendritic cells. Hepatology 34(5):896\u2013905","journal-title":"Hepatology"},{"issue":"5","key":"3092_CR49","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.7314\/APJCP.2013.14.5.3109","volume":"14","author":"S Su","year":"2013","unstructured":"Su S, Zhou H, Xue M, Liu JY, Ding L, Cao M et al (2013) Anti-tumor efficacy of a hepatocellular carcinoma vaccine based on dendritic cells combined with tumor-derived autophagosomes in murine models. Asian Pac J Cancer Prev 14(5):3109\u20133116","journal-title":"Asian Pac J Cancer Prev"},{"issue":"8","key":"3092_CR50","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s12094-013-1145-7","volume":"16","author":"BH Xie","year":"2014","unstructured":"Xie BH, Yang JY, Li HP, Zhang B, Chen W, Zhou B et al (2014) Dendritic cells transfected with hepatocellular carcinoma (HCC) total RNA induce specific immune responses against HCC in vitro and in vivo. Clin Transl Oncol 16(8):753\u2013760","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"3092_CR51","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.3892\/mmr.2016.4884","volume":"13","author":"J Zhou","year":"2016","unstructured":"Zhou J, Ma P, Li J, Cui X, Song W (2016) Improvement of the cytotoxic T lymphocyte response against hepatocellular carcinoma by transduction of cancer cells with an adeno-associated virus carrying the interferon-gamma gene. Mol Med Rep 13(4):3197\u20133205","journal-title":"Mol Med Rep"},{"issue":"1","key":"3092_CR52","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3748\/wjg.v10.i1.53","volume":"10","author":"SY Lu","year":"2004","unstructured":"Lu SY, Sui YF, Li ZS, Ye J, Dong HL, Qu P et al (2004) Superantigen-SEA gene modified tumor vaccine for hepatocellular carcinoma: an in vitro study. World J Gastroenterol 10(1):53\u201357","journal-title":"World J Gastroenterol"},{"issue":"6","key":"3092_CR53","first-page":"1397","volume":"22","author":"G Schueller","year":"2003","unstructured":"Schueller G, Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Benkoe T et al (2003) Hyperthermia improves cellular immune response to human hepatocellular carcinoma subsequent to co-culture with tumor lysate pulsed dendritic cells. Int J Oncol 22(6):1397\u20131402","journal-title":"Int J Oncol"},{"issue":"10","key":"3092_CR54","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/aps.2015.41","volume":"36","author":"C Sun","year":"2015","unstructured":"Sun C, Sun HY, Xiao WH, Zhang C, Tian ZG (2015) Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. Acta Pharmacol Sin 36(10):1191\u20131199","journal-title":"Acta Pharmacol Sin"},{"issue":"7","key":"3092_CR55","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s00705-013-1965-3","volume":"159","author":"Z Shabani","year":"2014","unstructured":"Shabani Z, Bagheri M, Zare-Bidaki M, Hassanshahi G, Arababadi MK, Nejad MM et al (2014) NK cells in hepatitis B virus infection: a potent target for immunotherapy. Arch Virol 159(7):1555\u20131565","journal-title":"Arch Virol"},{"issue":"12","key":"3092_CR56","doi-asserted-by":"publisher","first-page":"e26622","DOI":"10.4161\/onci.26622","volume":"2","author":"E Cariani","year":"2013","unstructured":"Cariani E, Missale G (2013) KIR\/HLA immunogenetic background influences the evolution of hepatocellular carcinoma. Oncoimmunology 2(12):e26622","journal-title":"Oncoimmunology"},{"issue":"12","key":"3092_CR57","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1158\/1535-7163.MCT-12-1087","volume":"12","author":"X Sun","year":"2013","unstructured":"Sun X, Sui Q, Zhang C, Tian Z, Zhang J (2013) Targeting Blockage of STAT3 in Hepatocellular Carcinoma Cells Augments NK Cell Functions via Reverse Hepatocellular Carcinoma-Induced Immune Suppression. Mol Cancer Ther 12(12):2885\u20132896","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"3092_CR58","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.imbio.2014.03.007","volume":"219","author":"W Jiang","year":"2014","unstructured":"Jiang W, Zhang C, Tian Z, Zhang J (2014) hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo. Immunobiology 219(7):547\u2013553","journal-title":"Immunobiology"},{"issue":"7","key":"3092_CR59","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1158\/2326-6066.CIR-15-0229","volume":"4","author":"T Kamiya","year":"2016","unstructured":"Kamiya T, Chang YH, Campana D (2016) Expanded and activated natural killer cells for immunotherapy of hepatocellular carcinoma. Cancer Immunol Res 4(7):574\u2013581","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"3092_CR60","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.3892\/ol.2016.4170","volume":"11","author":"ZF Hong","year":"2016","unstructured":"Hong ZF, Zhao WX, Yin ZY, Xie CR, Xu YP, Chi XQ et al (2016) Natural killer cells inhibit pulmonary metastasis of hepatocellular carcinoma in nude mice. Oncol Lett 11(3):2019\u20132026","journal-title":"Oncol Lett"},{"issue":"3","key":"3092_CR61","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10238-003-0023-y","volume":"3","author":"AM Attallah","year":"2003","unstructured":"Attallah AM, Tabll AA, El-Sadany M, Ibrahim TA, El-Dosoky I (2003) Dysregulation of blood lymphocyte subsets and natural killer cells in schistosomal liver cirrhosis and hepatocellular carcinoma. Clin Exp Med 3(3):181\u2013185","journal-title":"Clin Exp Med"},{"issue":"17","key":"3092_CR62","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.4254\/wjh.v7.i17.2080","volume":"7","author":"M Sachdeva","year":"2015","unstructured":"Sachdeva M, Chawla YK, Arora SK (2015) Immunology of hepatocellular carcinoma. World J Hepatol 7(17):2080\u20132090","journal-title":"World J Hepatol"},{"issue":"4","key":"3092_CR63","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F et al (2008) Sorafenib in advanced hepatocellular carcinoma. New Eng J Med 359(4):378\u2013390","journal-title":"New Eng J Med"},{"issue":"4","key":"3092_CR64","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00262-012-1380-8","volume":"62","author":"R Cabrera","year":"2013","unstructured":"Cabrera R, Ararat M, Xu Y, Brusko T, Wasserfall C, Atkinson MA et al (2013) Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma. Cancer Immunol Immunother 62(4):737\u2013746","journal-title":"Cancer Immunol Immunother"},{"key":"3092_CR65","doi-asserted-by":"publisher","first-page":"607851","DOI":"10.1155\/2012\/607851","volume":"2012","author":"H Nagai","year":"2012","unstructured":"Nagai H, Mukozu T, Matsui D, Kanekawa T, Kanayama M, Wakui N et al (2012) Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma. Clinical Dev Immunol 2012:607851","journal-title":"Clinical Dev Immunol"},{"issue":"2","key":"3092_CR66","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.surg.2014.03.031","volume":"156","author":"JW Ady","year":"2014","unstructured":"Ady JW, Heffner J, Mojica K, Johnsen C, Belin LJ, Love D et al (2014) Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently. Surgery 156(2):263\u2013269","journal-title":"Surgery"},{"issue":"2","key":"3092_CR67","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1158\/1535-7163.MCT-11-0412","volume":"11","author":"WT Tai","year":"2012","unstructured":"Tai WT, Cheng AL, Shiau CW, Liu CY, Ko CH, Lin MW et al (2012) Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. Mol Cancer Ther 11(2):452\u2013463","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"3092_CR68","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.bcp.2011.12.035","volume":"83","author":"KF Chen","year":"2012","unstructured":"Chen KF, Chen HL, Liu CY, Tai WT, Ichikawa K, Chen PJ et al (2012) Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. Biochem Pharmacol 83(6):769\u2013777","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"3092_CR69","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1002\/ijc.27604","volume":"131","author":"Z Ezzoukhry","year":"2012","unstructured":"Ezzoukhry Z, Louandre C, Trecherel E, Godin C, Chauffert B, Dupont S et al (2012) EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer 131(12):2961\u20132969","journal-title":"Int J Cancer"},{"issue":"3","key":"3092_CR70","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1440-1746.2012.07060.x","volume":"27","author":"T Maheswaran","year":"2012","unstructured":"Maheswaran T, Rushbrook SM (2012) Epithelial-mesenchymal transition and the liver: role in hepatocellular carcinoma and liver fibrosis. J Gastroenterol Hepatol 27(3):418\u2013420","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"3092_CR71","doi-asserted-by":"publisher","first-page":"e109992","DOI":"10.1371\/journal.pone.0109992","volume":"9","author":"HY Chuang","year":"2014","unstructured":"Chuang HY, Chang YF, Liu RS, Hwang JJ (2014) Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment. PLoS ONE 9(10):e109992","journal-title":"PLoS ONE"},{"issue":"10","key":"3092_CR72","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrclinonc.2011.116","volume":"8","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA (2011) Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol 8(10):577\u2013585","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"3092_CR73","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.1882","volume":"14","author":"MA Pule","year":"2008","unstructured":"Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G et al (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14(11):1264\u20131270","journal-title":"Nat Med"},{"issue":"32","key":"3092_CR74","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","volume":"26","author":"ME Dudley","year":"2008","unstructured":"Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U et al (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26(32):5233\u20135239","journal-title":"J Clin Oncol"},{"issue":"13","key":"3092_CR75","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ et al (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17(13):4550\u20134557","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3092_CR76","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.18632\/oncotarget.2835","volume":"6","author":"H Hu","year":"2015","unstructured":"Hu H, Qiu Y, Guo M, Huang Y, Fang L, Peng Z et al (2015) Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models. Oncotarget 6(2):1079\u20131089","journal-title":"Oncotarget"},{"issue":"3","key":"3092_CR77","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.3892\/ol.2016.4109","volume":"11","author":"R Li","year":"2016","unstructured":"Li R, Yan F, Liu L, Li H, Ren B, Hui Z et al (2016) Cytokine-induced killer cell therapy for the treatment of primary hepatocellular carcinoma subsequent to liver transplantation: a case report. Oncol Lett 11(3):1885\u20131888","journal-title":"Oncol Lett"},{"issue":"12","key":"3092_CR78","doi-asserted-by":"publisher","first-page":"e1051297","DOI":"10.1080\/2162402X.2015.1051297","volume":"4","author":"A Pedroza-Gonzalez","year":"2015","unstructured":"Pedroza-Gonzalez A, Zhou G, Singh SP, Boor PP, Pan Q, Grunhagen D et al (2015) GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells. Oncoimmunology 4(12):e1051297","journal-title":"Oncoimmunology"},{"issue":"5","key":"3092_CR79","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00109-014-1143-4","volume":"92","author":"Y Han","year":"2014","unstructured":"Han Y, Yang Y, Chen Z, Jiang Z, Gu Y, Liu Y et al (2014) Human hepatocellular carcinoma-infiltrating CD4+ CD69+ Foxp3\u2212 regulatory T cell suppresses T cell response via membrane-bound TGF-\u03b21. J Mol Med 92(5):539\u2013550","journal-title":"J Mol Med"},{"issue":"3","key":"3092_CR80","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00262-016-1800-2","volume":"65","author":"TT Spear","year":"2016","unstructured":"Spear TT, Callender GG, Roszkowski JJ, Moxley KM, Simms PE, Foley KC et al (2016) TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunol Immunother 65(3):293\u2013304","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"3092_CR81","first-page":"103","volume":"20","author":"NA Habib","year":"1996","unstructured":"Habib NA, Ding SF, El-Masry R, Mitry RR, Honda K, Michail NE et al (1996) Preliminary report: the short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas. Cancer Detect Prev 20(2):103\u2013107","journal-title":"Cancer Detect Prev"},{"issue":"3","key":"3092_CR82","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/mt.2013.277","volume":"22","author":"Cl Leboeuf","year":"2014","unstructured":"Leboeuf Cl, Mailly L, Wu T, Bour G, Durand S, Brignon N et al (2014) In Vivo Proof of Concept of Adoptive Immunotherapy for Hepatocellular Carcinoma Using Allogeneic Suicide Gene-modified Killer Cells. Mol Ther 22(3):634\u2013644","journal-title":"Mol Ther"},{"issue":"3","key":"3092_CR83","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.3892\/mmr.2016.4811","volume":"13","author":"T Wu","year":"2016","unstructured":"Wu T, Leboeuf C, Durand S, Su B, Deschamps M, Zhang X et al (2016) Suicide gene-modified killer cells as an allogeneic alternative to autologous cytokine-induced killer cell immunotherapy of hepatocellular carcinoma. Mol Med Rep 13(3):2645\u20132654","journal-title":"Mol Med Rep"},{"issue":"3","key":"3092_CR84","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3892\/ol.2013.1470","volume":"6","author":"L He","year":"2013","unstructured":"He L, Gong HX, Li XP, Wang YD, Li Y, Huang JJ et al (2013) Inhibition of hepatocellular carcinoma growth by adenovirus-mediated expression of human telomerase reverse transcriptase COOH-27 terminal polypeptide in mice. Oncol Lett 6(3):748\u2013752","journal-title":"Oncol Lett"},{"issue":"1","key":"3092_CR85","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s13277-015-3845-9","volume":"37","author":"L Sun","year":"2016","unstructured":"Sun L, Guo H, Jiang R, Lu L, Liu T, He X (2016) Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma. Tumour Biol 37(1):799\u2013806","journal-title":"Tumour Biol"},{"issue":"6","key":"3092_CR86","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3892\/ijmm.2013.1510","volume":"32","author":"Y Chen","year":"2013","unstructured":"Chen Y, Huang A, Gao M, Yan Y, Zhang W (2013) Potential therapeutic value of dendritic cells loaded with NY-ESO-1 protein for the immunotherapy of advanced hepatocellular carcinoma. Int J Mol Med 32(6):1366\u20131372","journal-title":"Int J Mol Med"},{"issue":"1","key":"3092_CR87","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13550-014-0029-3","volume":"4","author":"K Fujiwara","year":"2014","unstructured":"Fujiwara K, Koyama K, Suga K, Ikemura M, Saito Y, Hino A et al (2014) A 90 Y-labelled anti-ROBO1 monoclonal antibody exhibits antitumour activity against hepatocellular carcinoma xenografts during ROBO1-targeted radioimmunotherapy. EJNMMI Res 4(1):29","journal-title":"EJNMMI Res"},{"key":"3092_CR88","first-page":"1061","volume":"7","author":"AM Aref","year":"2014","unstructured":"Aref AM, Hoa NT, Ge L, Agrawal A, Dacosta-Iyer M, Lambrecht N et al (2014) HCA519\/TPX2: a potential T-cell tumor-associated antigen for human hepatocellular carcinoma. Onco Targets Ther 7:1061\u20131070","journal-title":"Onco Targets Ther"},{"issue":"7","key":"3092_CR89","doi-asserted-by":"publisher","first-page":"980","DOI":"10.4254\/wjh.v7.i7.980","volume":"7","author":"YP Hong","year":"2015","unstructured":"Hong YP, Li ZD, Prasoon P, Zhang Q (2015) Immunotherapy for hepatocellular carcinoma: from basic research to clinical use. World J Hepatol 7(7):980\u2013992","journal-title":"World J Hepatol"},{"issue":"8","key":"3092_CR90","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrd4591","volume":"14","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Rennert PD, Freeman GJ (2015) Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 14(8):561\u2013584","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"3092_CR91","doi-asserted-by":"publisher","first-page":"e000042","DOI":"10.1136\/esmoopen-2016-000042","volume":"1","author":"M Pinter","year":"2016","unstructured":"Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W (2016) Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open 1(2):e000042","journal-title":"ESMO Open"},{"key":"3092_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3402\/nano.v3i0.18496","volume":"3","author":"GL Zwicke","year":"2012","unstructured":"Zwicke GL, Mansoori GA, Jeffery CJ (2012) Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev 3:1\u201317","journal-title":"Nano Rev"},{"issue":"8","key":"3092_CR93","doi-asserted-by":"publisher","first-page":"8027","DOI":"10.1021\/nn502074x","volume":"8","author":"D Ling","year":"2014","unstructured":"Ling D, Xia H, Park W, Hackett MJ, Song C, Na K et al (2014) pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma. ACS Nano 8(8):8027\u20138039","journal-title":"ACS Nano"},{"issue":"6","key":"3092_CR94","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.humimm.2014.02.018","volume":"75","author":"V Bagheri","year":"2014","unstructured":"Bagheri V, Askari A, Arababadi MK, Kennedy D (2014) Can Toll-Like Receptor (TLR) 2 be considered as a new target for immunotherapy against hepatitis B infection? Hum Immunol 75(6):549\u2013554","journal-title":"Hum Immunol"},{"issue":"9","key":"3092_CR95","first-page":"6048","volume":"7","author":"X Lu","year":"2014","unstructured":"Lu X, Xu Q, Bu X, Ma X, Zhang F, Deng Q et al (2014) Relationship between expression of toll-like receptors 2\/4 in dendritic cells and chronic hepatitis B virus infection. Int J Clin Exp Pathol 7(9):6048\u20136055","journal-title":"Int J Clin Exp Pathol"},{"issue":"6","key":"3092_CR96","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.humimm.2014.02.018","volume":"75","author":"V Bagheri","year":"2014","unstructured":"Bagheri V, Askari A, Arababadi MK, Kennedy D (2014) Can Toll-Like Receptor (TLR) 2 be considered as a new target for immunotherapy against hepatitis B infection? Hum Immunol 75(6):549\u2013554","journal-title":"Hum Immunol"},{"issue":"4","key":"3092_CR97","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00262-014-1518-y","volume":"63","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Lin A, Zhang C, Tian Z, Zhang J (2014) Phosphorothioate-modified CpG oligodeoxynucleotide (CpG ODN) induces apoptosis of human hepatocellular carcinoma cells independent of TLR9. Cancer Immunol Immunother 63(4):357\u2013367","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"3092_CR98","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1245\/s10434-014-4191-7","volume":"22","author":"M Duan","year":"2015","unstructured":"Duan M, Wang ZC, Wang XY, Shi JY, Yang LX, Ding ZB et al (2015) TREM-1, an inflammatory modulator, is expressed in hepatocellular carcinoma cells and significantly promotes tumor progression. Ann Surg Oncol 22(9):3121\u20133129","journal-title":"Ann Surg Oncol"},{"issue":"16","key":"3092_CR99","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1158\/0008-5472.CAN-12-0938","volume":"72","author":"J Wu","year":"2012","unstructured":"Wu J, Li J, Salcedo R, Mivechi NF, Trinchieri G, Horuzsko A (2012) The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Cancer Res 72(16):3977\u20133986","journal-title":"Cancer Res"},{"key":"3092_CR100","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.bbamcr.2015.02.012","volume":"1853","author":"EB Cepeda","year":"2015","unstructured":"Cepeda EB, Dediulia T, Fernando J, Bertran E, Egea G, Navarro E et al (2015) Mechanisms regulating cell membrane localization of the chemokine receptor CXCR4 in human hepatocarcinoma cells. Biochim Biophys Acta 1853:1205\u20131218","journal-title":"Biochim Biophys Acta"},{"key":"3092_CR101","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.2147\/DDDT.S86032","volume":"9","author":"F Hu","year":"2015","unstructured":"Hu F, Miao L, Zhao Y, Xiao YY, Xu Q (2015) A meta-analysis for C-X-C chemokine receptor type 4 as a prognostic marker and potential drug target in hepatocellular carcinoma. Drug Des Dev Ther 9:3625\u20133633","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"3092_CR102","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/hep.27798","volume":"62","author":"O Garcia-Irigoyen","year":"2015","unstructured":"Garcia-Irigoyen O, Latasa MU, Carotti S, Uriarte I, Elizalde M, Urtasun R et al (2015) Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1\/C-X-C chemokine receptor 4 axis. Hepatology 62(1):166\u2013178","journal-title":"Hepatology"},{"issue":"1","key":"3092_CR103","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/gutjnl-2015-310514","volume":"66","author":"X Li","year":"2015","unstructured":"Li X, Yao W, Yuan Y, Chen P, Li B, Li J et al (2015) Targeting of tumour-infiltrating macrophages via CCL2\/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut 66(1):157\u2013167","journal-title":"Gut"},{"issue":"14","key":"3092_CR104","doi-asserted-by":"publisher","first-page":"7016","DOI":"10.1128\/JVI.00716-15","volume":"89","author":"Y Kondo","year":"2015","unstructured":"Kondo Y, Kimura O, Tanaka Y, Ninomiya M, Iwata T, Kogure T et al (2015) Differential expression of CX3CL1 in hepatitis B virus-replicating hepatoma cells can affect the migration activity of CX3CR1+ immune cells. J Virol 89(14):7016\u20137027","journal-title":"J Virol"},{"issue":"1","key":"3092_CR105","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/gutjnl-2015-310514","volume":"66","author":"X Li","year":"2017","unstructured":"Li X, Yao W, Yuan Y, Chen P, Li B, Li J et al (2017) Targeting of tumour-infiltrating macrophages via CCL2\/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut 66(1):157\u2013167","journal-title":"Gut"},{"issue":"2","key":"3092_CR106","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/1535-7163.MCT-16-0124","volume":"16","author":"KY Teng","year":"2017","unstructured":"Teng KY, Han J, Zhang X, Hsu SH, He S, Wani N et al (2017) Blocking the CCL2-CCR2 axis using CCL2 neutralizing antibody is an effective therapy for hepatocellular cancer in a mouse model. Mol Cancer Ther 16(2):312\u2013322","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"3092_CR107","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/hep.26403","volume":"58","author":"N Barashi","year":"2013","unstructured":"Barashi N, Weiss ID, Wald O, Wald H, Beider K, Abraham M et al (2013) Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice. Hepatology 58(3):1021\u20131030","journal-title":"Hepatology"},{"issue":"4","key":"3092_CR108","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/stem.2275","volume":"34","author":"Y Gao","year":"2016","unstructured":"Gao Y, Zhou Z, Lu S, Huang X, Zhang C, Jiang R et al (2016) Chemokine CCL15 mediates migration of human bone marrow-derived mesenchymal stem cells toward hepatocellular carcinoma. Stem Cells 34(4):1112\u20131122","journal-title":"Stem Cells"},{"issue":"3","key":"3092_CR109","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s12072-015-9683-4","volume":"10","author":"Y Li","year":"2016","unstructured":"Li Y, Yu HP, Zhang P (2016) CCL15 overexpression predicts poor prognosis for hepatocellular carcinoma. Hepatol Int 10(3):488\u2013492","journal-title":"Hepatol Int"},{"issue":"4","key":"3092_CR110","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1007\/s13277-015-4287-0","volume":"37","author":"Y Li","year":"2016","unstructured":"Li Y, Wu J, Zhang P (2016) CCL15\/CCR1 axis is involved in hepatocellular carcinoma cells migration and invasion. Tumour Biol 37(4):4501\u20134507","journal-title":"Tumour Biol"},{"issue":"2","key":"3092_CR111","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12032-016-0729-9","volume":"33","author":"F Zhu","year":"2016","unstructured":"Zhu F, Li X, Chen S, Zeng Q, Zhao Y, Luo F (2016) Tumor-associated macrophage or chemokine ligand CCL17 positively regulates the tumorigenesis of hepatocellular carcinoma. Med Oncol 33(2):17","journal-title":"Med Oncol"},{"issue":"1","key":"3092_CR112","first-page":"5","volume":"37","author":"X Chang","year":"2015","unstructured":"Chang X, Wang L, Zang M, Rong W, Wu Z, Liu L et al (2015) Relationship between CCL20\/CCR6\/Th17 axis and vascular invasion and metastasis in patients with primary hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 37(1):5\u201310","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"1","key":"3092_CR113","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/hep.26395","volume":"58","author":"T Pusterla","year":"2013","unstructured":"Pusterla T, Nemeth J, Stein I, Wiechert L, Knigin D, Marhenke S et al (2013) Receptor for advanced glycation endproducts (RAGE) is a key regulator of oval cell activation and inflammation-associated liver carcinogenesis in mice. Hepatology 58(1):363\u2013373","journal-title":"Hepatology"},{"issue":"12","key":"3092_CR114","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1055\/s-0042-120417","volume":"54","author":"N Buttner","year":"2016","unstructured":"Buttner N, Schmidt N, Thimme R (2016) Perspectives of immunotherapy in hepatocellular carcinoma (HCC). Z Gastroenterol 54(12):1334\u20131342","journal-title":"Z Gastroenterol"},{"issue":"1","key":"3092_CR115","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2174\/157488708783330549","volume":"3","author":"TF Greten","year":"2008","unstructured":"Greten TF, Manns MP, Korangy F (2008) Immunotherapy of HCC. Rev Recent Clin Trials 3(1):31\u201339","journal-title":"Rev Recent Clin Trials"},{"issue":"6","key":"3092_CR116","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jhep.2006.09.004","volume":"45","author":"TF Greten","year":"2006","unstructured":"Greten TF, Manns MP, Korangy F (2006) Immunotherapy of hepatocellular carcinoma. J Hepatol 45(6):868\u2013878","journal-title":"J Hepatol"},{"issue":"4","key":"3092_CR117","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1440-1746.1989.tb00848.x","volume":"4","author":"MC Kew","year":"1989","unstructured":"Kew MC (1989) Tumour markers of hepatocellular carcinoma. J Gastroenterol Hepatol 4(4):373\u2013384","journal-title":"J Gastroenterol Hepatol"},{"issue":"2C","key":"3092_CR118","first-page":"1747","volume":"23","author":"M Soresi","year":"2002","unstructured":"Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A et al (2002) Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res 23(2C):1747\u20131753","journal-title":"Anticancer Res"},{"issue":"13","key":"3092_CR119","first-page":"3064","volume":"59","author":"CM Vollmer Jr","year":"1999","unstructured":"Vollmer CM Jr, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A et al (1999) Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 59(13):3064\u20133067","journal-title":"Cancer Res"},{"issue":"4","key":"3092_CR120","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1053\/gast.2000.18157","volume":"119","author":"CF Grimm","year":"2000","unstructured":"Grimm CF, Dr Ortmann, Mohr L, Michalak S, Krohne TU, Meckel S et al (2000) Mouse \u03b1-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology 119(4):1104\u20131112","journal-title":"Gastroenterology"},{"key":"3092_CR121","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40425-015-0077-x","volume":"3","author":"AD Pardee","year":"2015","unstructured":"Pardee AD, Yano H, Weinstein AM, Ponce AA, Ethridge AD, Normolle DP et al (2015) Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma. J Immunother Cancer 3:32","journal-title":"J Immunother Cancer"},{"issue":"14","key":"3092_CR122","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1158\/0008-5472.CAN-04-4244","volume":"65","author":"MI Capurro","year":"2005","unstructured":"Capurro MI, Xiang YY, Lobe C, Filmus J (2005) Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 65(14):6245\u20136254","journal-title":"Cancer Res"},{"key":"3092_CR123","first-page":"1403","volume":"8","author":"H Shirakawa","year":"2003","unstructured":"Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S et al (2003) Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 8:1403\u20131407","journal-title":"Cancer Sci"},{"issue":"1","key":"3092_CR124","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0016-5085(03)00689-9","volume":"125","author":"M Capurro","year":"2003","unstructured":"Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E et al (2003) Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125(1):89\u201397","journal-title":"Gastroenterology"},{"issue":"10","key":"3092_CR125","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1111\/febs.12126","volume":"280","author":"J Filmus","year":"2013","unstructured":"Filmus J, Capurro M (2013) Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS J 280(10):2471\u20132476","journal-title":"FEBS J"},{"issue":"2","key":"3092_CR126","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/hep.22709","volume":"49","author":"M Kojiro","year":"2009","unstructured":"Kojiro M, Wanless IR, Alves V, Badve S, Balabaud C, Bedossa P et al (2009) Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49(2):658\u2013664","journal-title":"Hepatology"},{"issue":"6","key":"3092_CR127","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.4161\/hv.24179","volume":"9","author":"Y Sawada","year":"2013","unstructured":"Sawada Y, Yoshikawa T, Fujii S, Mitsunaga S, Nobuoka D, Mizuno S et al (2013) Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: an autopsy case. Hum Vaccin Immunother 9(6):1228\u20131233","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"3092_CR128","doi-asserted-by":"publisher","first-page":"E1083","DOI":"10.1073\/pnas.1217868110","volume":"110","author":"M Feng","year":"2013","unstructured":"Feng M, Gao W, Wang R, Chen W, Man Y-G, Figg WD et al (2013) Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci USA 110(12):E1083\u2013E1091","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"3092_CR129","doi-asserted-by":"publisher","first-page":"9832","DOI":"10.1158\/0008-5472.CAN-08-1973","volume":"68","author":"T Ishiguro","year":"2008","unstructured":"Ishiguro T, Sugimoto M, Kinoshita Y, Miyazaki Y, Nakano K, Tsunoda H et al (2008) Anti-glypican3 antibody for treatment of human liver cancer. Cancer Res 68(23):9832\u20139838","journal-title":"Cancer Res"},{"issue":"6","key":"3092_CR130","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1021\/acs.molpharmaceut.5b00132","volume":"12","author":"H Hanaoka","year":"2015","unstructured":"Hanaoka H, Nagaya T, Sato K, Nakamura Y, Watanabe R, Harada T et al (2015) Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy. Mol Pharm 12(6):2151\u20132157","journal-title":"Mol Pharm"},{"issue":"2","key":"3092_CR131","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/hep.26996","volume":"60","author":"W Gao","year":"2014","unstructured":"Gao W, Kim H, Feng M, Phung Y, Xavier CP, Rubin JS et al (2014) Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology 60(2):576\u2013587","journal-title":"Hepatology"},{"issue":"9","key":"3092_CR132","doi-asserted-by":"publisher","first-page":"e0137664","DOI":"10.1371\/journal.pone.0137664","volume":"10","author":"W Gao","year":"2015","unstructured":"Gao W, Kim H, Ho M (2015) Human monoclonal antibody targeting the heparan sulfate chains of glypican-3 inhibits HGF-mediated migration and motility of hepatocellular carcinoma cells. PLoS ONE 10(9):e0137664","journal-title":"PLoS ONE"},{"issue":"8","key":"3092_CR133","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1593\/neo.11664","volume":"13","author":"CK Sun","year":"2011","unstructured":"Sun CK, Chua MS, He J, So SK (2011) Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-beta2. Neoplasia 13(8):735\u2013747","journal-title":"Neoplasia"},{"key":"3092_CR134","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ejphar.2014.11.008","volume":"746","author":"RA Zaghloul","year":"2015","unstructured":"Zaghloul RA, El-Shishtawy MM, El Galil KH, Ebrahim MA, Metwaly AA, Al-Gayyar MM (2015) Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma. Eur J Pharmacol 746:353\u2013362","journal-title":"Eur J Pharmacol"},{"issue":"24","key":"3092_CR135","doi-asserted-by":"publisher","first-page":"6418","DOI":"10.1158\/1078-0432.CCR-14-1170","volume":"20","author":"H Gao","year":"2014","unstructured":"Gao H, Li K, Tu H, Pan X, Jiang H, Shi B et al (2014) Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res 20(24):6418\u20136428","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3092_CR136","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.febslet.2013.10.002","volume":"588","author":"M Feng","year":"2014","unstructured":"Feng M, Ho M (2014) Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett 588(2):377\u2013382","journal-title":"FEBS Lett"},{"issue":"130","key":"3092_CR137","first-page":"278","volume":"61","author":"SQ Li","year":"2014","unstructured":"Li SQ, Lin J, Qi CY, Fu SJ, Xiao WK, Peng BG et al (2014) GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice. Hepatogastroenterology 61(130):278\u2013284","journal-title":"Hepatogastroenterology"},{"issue":"3","key":"3092_CR138","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3892\/or.2014.3300","volume":"32","author":"C Luo","year":"2014","unstructured":"Luo C, Shibata K, Suzuki S, Kajiyama H, Senga T, Koya Y et al (2014) GPC3 expression in mouse ovarian cancer induces GPC3-specific T cell-mediated immune response through M1 macrophages and suppresses tumor growth. Oncol Rep 32(3):913\u2013921","journal-title":"Oncol Rep"},{"issue":"7","key":"3092_CR139","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nrc842","volume":"2","author":"R Sasisekharan","year":"2002","unstructured":"Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U (2002) Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2(7):521\u2013528","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3092_CR140","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.jhep.2008.12.023","volume":"50","author":"CJ Liu","year":"2009","unstructured":"Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW et al (2009) Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 50(5):958\u2013968","journal-title":"J Hepatol"},{"issue":"3","key":"3092_CR141","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1007\/s13277-015-4085-8","volume":"37","author":"BY Liao","year":"2016","unstructured":"Liao BY, Wang Z, Hu J, Liu WF, Shen ZZ, Zhang X et al (2016) PI-88 inhibits postoperative recurrence of hepatocellular carcinoma via disrupting the surge of heparanase after liver resection. Tumour Biol 37(3):2987\u20132998","journal-title":"Tumour Biol"},{"issue":"32","key":"3092_CR142","doi-asserted-by":"publisher","first-page":"11384","DOI":"10.3748\/wjg.v20.i32.11384","volume":"20","author":"CJ Liu","year":"2014","unstructured":"Liu CJ, Chang J, Lee PH, Lin DY, Wu CC, Jeng LB et al (2014) Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. World J Gastroenterol 20(32):11384\u201311393","journal-title":"World J Gastroenterol"},{"issue":"42","key":"3092_CR143","doi-asserted-by":"publisher","first-page":"32638","DOI":"10.1074\/jbc.M110.105544","volume":"285","author":"H Qiu","year":"2010","unstructured":"Qiu H, Yang B, Pei ZC, Zhang Z, Ding K (2010) WSS25 inhibits growth of xenografted hepatocellular cancer cells in nude mice by disrupting angiogenesis via blocking bone morphogenetic protein (BMP)\/Smad\/Id1 signaling. J Biol Chem 285(42):32638\u201332646","journal-title":"J Biol Chem"},{"issue":"6","key":"3092_CR144","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1189\/jlb.0506297","volume":"80","author":"A Budhu","year":"2006","unstructured":"Budhu A, Wang XW (2006) The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 80(6):1197\u20131213","journal-title":"J Leukoc Biol"},{"issue":"3","key":"3092_CR145","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s12072-013-9441-4","volume":"7","author":"M Gelu-Simeon","year":"2013","unstructured":"Gelu-Simeon M, Samuel D (2013) Role of cytokine levels in assessment of prognosis and post-treatment outcome in hepatocellular carcinoma. Hepatol Int 7(3):788\u2013791","journal-title":"Hepatol Int"},{"issue":"3","key":"3092_CR146","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/bjc.2013.781","volume":"110","author":"ZY Chen","year":"2014","unstructured":"Chen ZY, Wei W, Guo ZX, Peng LX, Shi M, Li SH et al (2014) Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts. Br J Cancer 110(3):733\u2013740","journal-title":"Br J Cancer"},{"issue":"11","key":"3092_CR147","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1517\/14712598.7.11.1705","volume":"7","author":"JM Weiss","year":"2007","unstructured":"Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH (2007) Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 7(11):1705\u20131721","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"3092_CR148","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1053\/j.gastro.2015.02.055","volume":"148","author":"JH Lee","year":"2015","unstructured":"Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY et al (2015) Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 148(7):1383\u20131391","journal-title":"Gastroenterology"},{"issue":"11","key":"3092_CR149","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.dld.2016.07.010","volume":"48","author":"H Wang","year":"2016","unstructured":"Wang H, Liu A, Bo W, Feng X, Hu Y, Tian L et al (2016) Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma patients after curative resection, a systematic review and meta-analysis. Dig Liver Dis 48(11):1275\u20131282","journal-title":"Dig Liver Dis"},{"issue":"1","key":"3092_CR150","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/2162-3619-1-11","volume":"1","author":"Y Ma","year":"2012","unstructured":"Ma Y, Xu YC, Tang L, Zhang Z, Wang J, Wang HX (2012) Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol 1(1):11","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"3092_CR151","first-page":"599","volume":"62","author":"Y Su","year":"2016","unstructured":"Su Y, Yang Y, Ma Y, Zhang Y, Rao W, Yang G et al (2016) The efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cell therapy in combination with TACE-predominant minimally-invasive treatment for hepatocellular carcinoma: a meta-analysis. Clin Lab 62(4):599\u2013608","journal-title":"Clin Lab"},{"issue":"4","key":"3092_CR152","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/hep.1840380412","volume":"38","author":"DR Nelson","year":"2003","unstructured":"Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu YL et al (2003) Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 38(4):859\u2013868","journal-title":"Hepatology"},{"key":"3092_CR153","first-page":"486407","volume":"2014","author":"CH Hung","year":"2014","unstructured":"Hung CH, Chiu YC, Chen CH, Hu TH (2014) MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target. Biomed Res Int 2014:486407","journal-title":"Biomed Res Int"},{"issue":"7308","key":"3092_CR154","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nature09267","volume":"466","author":"H Guo","year":"2010","unstructured":"Guo H, Ingolia NT, Weissman JS, Bartel DP (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466(7308):835\u2013840","journal-title":"Nature"},{"issue":"6","key":"3092_CR155","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.chom.2008.05.002","volume":"3","author":"E Gottwein","year":"2008","unstructured":"Gottwein E, Cullen BR (2008) Viral and cellular microRNAs as determinants of viral pathogenesis and immunity. Cell Host Microbe 3(6):375\u2013387","journal-title":"Cell Host Microbe"},{"key":"3092_CR156","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev.cellbio.23.090506.123406","volume":"23","author":"N Bushati","year":"2007","unstructured":"Bushati N, Cohen SM (2007) microRNA functions. Annu Rev Cell Dev Biol 23:175\u2013205","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"6","key":"3092_CR157","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.jhep.2011.11.026","volume":"56","author":"F Borel","year":"2012","unstructured":"Borel F, Konstantinova P, Jansen PL (2012) Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 56(6):1371\u20131383","journal-title":"J Hepatol"},{"issue":"5","key":"3092_CR158","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1093\/carcin\/bgp250","volume":"31","author":"M Furuta","year":"2010","unstructured":"Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J (2010) miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 31(5):766\u2013776","journal-title":"Carcinogenesis"},{"issue":"7385","key":"3092_CR159","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nature10888","volume":"482","author":"A Lujambio","year":"2012","unstructured":"Lujambio A, Lowe SW (2012) The microcosmos of cancer. Nature 482(7385):347\u2013355","journal-title":"Nature"},{"issue":"1","key":"3092_CR160","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2011.04.026","volume":"56","author":"Y Tomimaru","year":"2012","unstructured":"Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S et al (2012) Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 56(1):167\u2013175","journal-title":"J Hepatol"},{"issue":"1","key":"3092_CR161","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cell.2005.06.036","volume":"122","author":"CM Croce","year":"2005","unstructured":"Croce CM, Calin GA (2005) miRNAs, cancer, and stem cell division. Cell 122(1):6\u20137","journal-title":"Cell"},{"issue":"11","key":"3092_CR162","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrc1997","volume":"6","author":"GA Calin","year":"2006","unstructured":"Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6(11):857\u2013866","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"3092_CR163","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/cr.2008.282","volume":"18","author":"X Chen","year":"2008","unstructured":"Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18(10):997\u20131006","journal-title":"Cell Res"},{"issue":"1","key":"3092_CR164","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/hep.26616","volume":"59","author":"A Petrelli","year":"2014","unstructured":"Petrelli A, Perra A, Cora D, Sulas P, Menegon S, Manca C et al (2014) MicroRNA\/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC). Hepatology 59(1):228\u2013241","journal-title":"Hepatology"},{"issue":"2","key":"3092_CR165","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mc.20712","volume":"50","author":"J Xu","year":"2011","unstructured":"Xu J, Wu C, Che X, Wang L, Yu D, Zhang T et al (2011) Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 50(2):136\u2013142","journal-title":"Mol Carcinog"},{"issue":"1","key":"3092_CR166","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.bbrc.2011.01.111","volume":"406","author":"J Li","year":"2011","unstructured":"Li J, Wang Y, Yu W, Chen J, Luo J (2011) Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 406(1):70\u201373","journal-title":"Biochem Biophys Res Commun"},{"issue":"23","key":"3092_CR167","doi-asserted-by":"publisher","first-page":"9798","DOI":"10.1158\/0008-5472.CAN-10-1001","volume":"70","author":"LM Li","year":"2010","unstructured":"Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang JF et al (2010) Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 70(23):9798\u20139807","journal-title":"Cancer Res"},{"issue":"2","key":"3092_CR168","doi-asserted-by":"publisher","first-page":"e000825","DOI":"10.1136\/bmjopen-2012-000825","volume":"2","author":"AM Liu","year":"2012","unstructured":"Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, Fan ST et al (2012) Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2(2):e000825","journal-title":"BMJ Open"},{"issue":"4","key":"3092_CR169","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/MCG.0b013e3181f18ac2","volume":"45","author":"KZ Qu","year":"2011","unstructured":"Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M (2011) Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 45(4):355\u2013360","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"3092_CR170","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jhep.2010.09.023","volume":"54","author":"P Gao","year":"2011","unstructured":"Gao P, Wong CC, Tung EK, Lee JM, Wong CM, Ng IO (2011) Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol 54(6):1177\u20131184","journal-title":"J Hepatol"},{"issue":"7","key":"3092_CR171","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1053\/j.gastro.2012.04.007","volume":"142","author":"XW Wang","year":"2012","unstructured":"Wang XW, Heegaard NH, Orum H (2012) MicroRNAs in liver disease. Gastroenterology 142(7):1431\u20131443","journal-title":"Gastroenterology"},{"issue":"10","key":"3092_CR172","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.1093\/nar\/gkr1278","volume":"40","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Lu Y, Zhang Q, Liu JJ, Li TJ, Yang JR et al (2012) MicroRNA-26a\/b and their host genes cooperate to inhibit the G1\/S transition by activating the pRb protein. Nucleic Acids Res 40(10):4615\u20134625","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"3092_CR173","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/hep.22806","volume":"49","author":"WC Tsai","year":"2009","unstructured":"Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM et al (2009) MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 49(5):1571\u20131582","journal-title":"Hepatology"},{"issue":"2","key":"3092_CR174","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.bbrc.2012.08.075","volume":"426","author":"Q Lang","year":"2012","unstructured":"Lang Q, Ling C (2012) MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA. Biochem Biophys Res Commun 426(2):247\u2013252","journal-title":"Biochem Biophys Res Commun"},{"issue":"46","key":"3092_CR175","doi-asserted-by":"publisher","first-page":"32015","DOI":"10.1074\/jbc.M109.016774","volume":"284","author":"S Bai","year":"2009","unstructured":"Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H et al (2009) MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 284(46):32015\u201332027","journal-title":"J Biol Chem"},{"issue":"3","key":"3092_CR176","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/hep.25747","volume":"56","author":"E Callegari","year":"2012","unstructured":"Callegari E, Elamin BK, Giannone F, Milazzo M, Altavilla G, Fornari F et al (2012) Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology 56(3):1025\u20131033","journal-title":"Hepatology"},{"issue":"2","key":"3092_CR177","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/hepr.12386","volume":"45","author":"A Morishita","year":"2015","unstructured":"Morishita A, Masaki T (2015) miRNA in hepatocellular carcinoma. Hepatol Res 45(2):128\u2013141","journal-title":"Hepatol Res"},{"issue":"10","key":"3092_CR178","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1038\/sj.bjc.6605958","volume":"103","author":"Y Tomimaru","year":"2010","unstructured":"Tomimaru Y, Eguchi H, Nagano H, Wada H, Tomokuni A, Kobayashi S et al (2010) MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha\/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 103(10):1617\u20131626","journal-title":"Br J Cancer"},{"issue":"12","key":"3092_CR179","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1038\/onc.2009.468","volume":"29","author":"B Wang","year":"2010","unstructured":"Wang B, Hsu S-H, Majumder S, Kutay H, Huang W, Jacob ST et al (2010) TGF\u03b2-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 29(12):1787\u20131797","journal-title":"Oncogene"},{"issue":"8","key":"3092_CR180","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/nbt1122","volume":"23","author":"DV Morrissey","year":"2005","unstructured":"Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W et al (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23(8):1002\u20131007","journal-title":"Nat Biotechnol"},{"issue":"3","key":"3092_CR181","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/nat.2011.0332","volume":"22","author":"ES Hildebrandt-Eriksen","year":"2012","unstructured":"Hildebrandt-Eriksen ES, Aarup V, Persson R, Hansen HF, Munk ME, Orum H (2012) A locked nucleic acid oligonucleotide targeting microRNA 122 is well-tolerated in cynomolgus monkeys. Nucleic Acid Ther 22(3):152\u2013161","journal-title":"Nucleic Acid Ther"},{"issue":"5962","key":"3092_CR182","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1126\/science.1178178","volume":"327","author":"RE Lanford","year":"2010","unstructured":"Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME et al (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327(5962):198\u2013201","journal-title":"Science"},{"issue":"12","key":"3092_CR183","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1073\/pnas.1016606108","volume":"108","author":"YP Li","year":"2011","unstructured":"Li YP, Gottwein JM, Scheel TK, Jensen TB, Bukh J (2011) MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5\u2032 UTR. Proc Natl Acad Sci USA 108(12):4991\u20134996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"3092_CR184","doi-asserted-by":"publisher","first-page":"e603","DOI":"10.1097\/MD.0000000000000603","volume":"94","author":"L Jiang","year":"2015","unstructured":"Jiang L, Cheng Q, Zhang BH, Zhang MZ (2015) Circulating microRNAs as biomarkers in hepatocellular carcinoma screening: a validation set from China. Medicine 94(10):e603","journal-title":"Medicine"},{"key":"3092_CR185","doi-asserted-by":"crossref","first-page":"924206","DOI":"10.1155\/2013\/924206","volume":"2013","author":"J Sun","year":"2013","unstructured":"Sun J, Lu H, Wang X, Jin H (2013) MicroRNAs in hepatocellular carcinoma: regulation, function, and clinical implications. Sci World J 2013:924206","journal-title":"Sci World J"},{"issue":"3","key":"3092_CR186","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4236\/ojim.2012.23024","volume":"2","author":"KS Ko","year":"2012","unstructured":"Ko KS, Peng H, Tang H, Cho ME, Peng J, Aller M-A et al (2012) Recent advances of miRNA involvement in hepatocellular carcinoma and cholangiocarcinoma. Open J Int Med 2(3):135\u2013162","journal-title":"Open J Int Med"},{"key":"3092_CR187","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.biopha.2016.09.056","volume":"84","author":"T Zhang","year":"2016","unstructured":"Zhang T, Liu W, Zeng XC, Jiang N, Fu BS, Guo Y et al (2016) Down-regulation of microRNA-338-3p promoted angiogenesis in hepatocellular carcinoma. Biomed Pharmacother 84:583\u2013591","journal-title":"Biomed Pharmacother"},{"key":"3092_CR188","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.biopha.2016.07.037","volume":"83","author":"H Zhu","year":"2016","unstructured":"Zhu H, Wang G, Zhou X, Song X, Gao H, Ma C et al (2016) miR-1299 suppresses cell proliferation of hepatocellular carcinoma (HCC) by targeting CDK6. Biomed Pharmacother 83:792\u2013797","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"3092_CR189","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1476-4598-12-153","volume":"12","author":"L Chen","year":"2013","unstructured":"Chen L, Zhou S, Qin J, Hu H, Ma H, Liu B et al (2013) Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma. Mol Cancer 12(1):153","journal-title":"Mol Cancer"},{"issue":"5","key":"3092_CR190","first-page":"674","volume":"34","author":"WW Guo","year":"2014","unstructured":"Guo WW, Liu L, Wu DH (2014) Dendritic cell-cytokine induced killer cell immunotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: safety and efficacy. Nan Fang Yi Ke Da Xue Xue Bao 34(5):674\u2013678","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"2","key":"3092_CR191","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1166\/jbn.2014.1766","volume":"10","author":"R Chen","year":"2014","unstructured":"Chen R, Yu H, An YL, Yu-Jia Z, Teng GJ (2014) Genetic immunotherapy for hepatocellular carcinoma by endothelial progenitor cells armed with cytosine deaminase. J Biomed Nanotechnol 10(2):271\u2013277","journal-title":"J Biomed Nanotechnol"},{"issue":"1","key":"3092_CR192","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000360993","volume":"87","author":"J Nemunaitis","year":"2014","unstructured":"Nemunaitis J, Barve M, Orr D, Kuhn J, Magee M, Lamont J et al (2014) Summary of bi-shRNA\/GM-CSF augmented autologous tumor cell immunotherapy (FANG) in advanced cancer of the liver. Oncology 87(1):21\u201329","journal-title":"Oncology"},{"issue":"1","key":"3092_CR193","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1185\/030079902125001362","volume":"19","author":"H Jozuka","year":"2003","unstructured":"Jozuka H, Jozuka E, Suzuki M, Takeuchi S, Takatsu Y (2003) Psycho-neuro-immunological treatment of hepatocellular carcinoma with major depression-a single case report. Curr Med Res Opin 19(1):59\u201363","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"3092_CR194","doi-asserted-by":"publisher","first-page":"970","DOI":"10.4161\/hv.27678","volume":"10","author":"K Shimizu","year":"2014","unstructured":"Shimizu K, Kotera Y, Aruga A, Takeshita N, Katagiri S, Ariizumi S et al (2014) Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma. Hum Vaccin Immunother 10(4):970\u2013976","journal-title":"Hum Vaccin Immunother"},{"issue":"13","key":"3092_CR195","first-page":"3605","volume":"63","author":"O Ebert","year":"2003","unstructured":"Ebert O, Shinozaki K, Huang TG, Savontaus MJ, Garcia-Sastre A, Woo SLC (2003) Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res 63(13):3605\u20133611","journal-title":"Cancer Res"},{"issue":"1","key":"3092_CR196","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/hep.20536","volume":"41","author":"K Shinozaki","year":"2005","unstructured":"Shinozaki K, Ebert O, Woo SLC (2005) Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology 41(1):196\u2013203","journal-title":"Hepatology"},{"issue":"3","key":"3092_CR197","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ymthe.2003.12.004","volume":"9","author":"K Shinozaki","year":"2004","unstructured":"Shinozaki K, Ebert O, Kournioti C, Tai YS, Woo SLC (2004) Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther 9(3):368\u2013376","journal-title":"Mol Ther"},{"key":"3092_CR198","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fonc.2014.00085","volume":"4","author":"J Altomonte","year":"2014","unstructured":"Altomonte J, Ebert O (2014) Sorting out Pandora\u2019s box: discerning the dynamic roles of liver microenvironment in oncolytic virus therapy for hepatocellular carcinoma. Front Oncol 4:85","journal-title":"Front Oncol"},{"issue":"2","key":"3092_CR199","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.surg.2015.03.044","volume":"158","author":"JW Ady","year":"2015","unstructured":"Ady JW, Johnsen C, Mojica K, Heffner J, Love D, Pugalenthi A et al (2015) Oncolytic gene therapy with recombinant vaccinia strain GLV-2b372 efficiently kills hepatocellular carcinoma. Surgery 158(2):331\u2013338","journal-title":"Surgery"},{"key":"3092_CR200","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13046-015-0271-1","volume":"34","author":"D Wei","year":"2015","unstructured":"Wei D, Li Q, Wang XL, Wang Y, Xu J, Feng F et al (2015) Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice. J Exp Clin Cancer Res 34:153","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"3092_CR201","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00432-014-1835-8","volume":"141","author":"B Ma","year":"2015","unstructured":"Ma B, Wang Y, Zhou X, Huang P, Zhang R, Liu T et al (2015) Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin. J Cancer Res Clin Oncol 141(3):419\u2013429","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"3092_CR202","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.4161\/cbt.29686","volume":"15","author":"FL Bai","year":"2014","unstructured":"Bai FL, Yu YH, Tian H, Ren GP, Wang H, Zhou B et al (2014) Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. Cancer Biol Ther 15(9):1226\u20131238","journal-title":"Cancer Biol Ther"},{"issue":"1\u20132","key":"3092_CR203","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.imlet.2014.02.009","volume":"159","author":"F Bai","year":"2014","unstructured":"Bai F, Niu Z, Tian H, Li S, Lv Z, Zhang T et al (2014) Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy. Immunol Lett 159(1\u20132):36\u201346","journal-title":"Immunol Lett"},{"issue":"9","key":"3092_CR204","first-page":"10403","volume":"8","author":"CY Qian","year":"2015","unstructured":"Qian CY, Wang KL, Fang FF, Gu W, Huang F, Wang FZ et al (2015) Triple-controlled oncolytic adenovirus expressing melittin to exert inhibitory efficacy on hepatocellular carcinoma. Int J Clin Exp Pathol 8(9):10403\u201310411","journal-title":"Int J Clin Exp Pathol"},{"issue":"15","key":"3092_CR205","doi-asserted-by":"publisher","first-page":"13564","DOI":"10.18632\/oncotarget.3769","volume":"6","author":"Y Wang","year":"2015","unstructured":"Wang Y, Liu T, Huang P, Zhao H, Zhang R, Ma B et al (2015) A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma. Oncotarget 6(15):13564\u201313578","journal-title":"Oncotarget"},{"issue":"10","key":"3092_CR206","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/cbr.2014.1642","volume":"29","author":"F Huang","year":"2014","unstructured":"Huang F, Ma B, Wang Y, Xiao R, Kong Y, Zhou X et al (2014) Targeting gene-virus-mediated manganese superoxide dismutase effectively suppresses tumor growth in hepatocellular carcinoma in vitro and in vivo. Cancer Biother Radiopharm 29(10):403\u2013411","journal-title":"Cancer Biother Radiopharm"},{"issue":"3","key":"3092_CR207","first-page":"282","volume":"8","author":"CY Mao","year":"2009","unstructured":"Mao CY, Hua HJ, Chen P, Yu DC, Cao J, Teng LS (2009) Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 8(3):282\u2013287","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"16","key":"3092_CR208","doi-asserted-by":"publisher","first-page":"7393","DOI":"10.1158\/0008-5472.CAN-04-3664","volume":"65","author":"T Wirth","year":"2005","unstructured":"Wirth T, K\u00fchnel F, Fleischmann-Mundt B, Woller N, Djojosubroto M, Rudolph KL et al (2005) Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. Cancer Res 65(16):7393\u20137402","journal-title":"Cancer Res"},{"issue":"10","key":"3092_CR209","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1136\/gut.2009.196519","volume":"59","author":"B Boozari","year":"2010","unstructured":"Boozari B, Mundt B, Woller N, Str\u00fcver N, G\u00fcrlevik E, Schache P et al (2010) Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma. Gut 59(10):1416\u20131426","journal-title":"Gut"},{"issue":"9","key":"3092_CR210","doi-asserted-by":"publisher","first-page":"e73964","DOI":"10.1371\/journal.pone.0073964","volume":"8","author":"E Callegari","year":"2013","unstructured":"Callegari E, Elamin BK, D\u2019Abundo L, Falzoni S, Donvito G, Moshiri F et al (2013) Anti-tumor activity of a miR-199-dependent oncolytic adenovirus. PLoS ONE 8(9):e73964","journal-title":"PLoS ONE"},{"issue":"6","key":"3092_CR211","doi-asserted-by":"publisher","first-page":"e65222","DOI":"10.1371\/journal.pone.0065222","volume":"8","author":"D Sharon","year":"2013","unstructured":"Sharon D, Schumann M, MacLeod S, McPherson R, Chaurasiya S, Shaw A et al (2013) 2-aminopurine enhances the oncolytic activity of an E1b-deleted adenovirus in hepatocellular carcinoma cells. PLoS ONE 8(6):e65222","journal-title":"PLoS ONE"},{"issue":"4","key":"3092_CR212","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00432-011-1138-2","volume":"138","author":"G He","year":"2012","unstructured":"He G, Lei W, Wang S, Xiao R, Guo K, Xia Y et al (2012) Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth. J Cancer Res Clin Oncol 138(4):657\u2013670","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"3092_CR213","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.molonc.2012.10.007","volume":"7","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Fang L, Zhang Q, Zheng Q, Tong J, Fu X et al (2013) An oncolytic adenovirus regulated by a radiation-inducible promoter selectively mediates hSulf-1 gene expression and mutually reinforces antitumor activity of I131-metuximab in hepatocellular carcinoma. Mol Oncol 7(3):346\u2013358","journal-title":"Mol Oncol"},{"key":"3092_CR214","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1186\/s12885-015-1753-4","volume":"15","author":"CH Kung","year":"2015","unstructured":"Kung CH, Kuo SC, Chen TL, Weng WS (2015) Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma. BMC Cancer 15:704","journal-title":"BMC Cancer"},{"issue":"3","key":"3092_CR215","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/mt.2014.243","volume":"23","author":"TP Cripe","year":"2015","unstructured":"Cripe TP, Ngo MC, Geller JI, Louis CU, Currier MA, Racadio JM et al (2015) Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther 23(3):602\u2013608","journal-title":"Mol Ther"},{"issue":"11","key":"3092_CR216","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/mt.2013.181","volume":"21","author":"J Altomonte","year":"2013","unstructured":"Altomonte J, Marozin S, De Toni EN, Rizzani A, Esposito I, Steiger K et al (2013) Antifibrotic properties of transarterial oncolytic VSV therapy for hepatocellular carcinoma in rats with thioacetamide-induced liver fibrosis. Mol Ther 21(11):2032\u20132042","journal-title":"Mol Ther"},{"issue":"6","key":"3092_CR217","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/cgt.2015.23","volume":"22","author":"S Marozin","year":"2015","unstructured":"Marozin S, Altomonte J, Munoz-Alvarez KA, Rizzani A, De Toni EN, Thasler WE et al (2015) STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma. Cancer Gene Ther 22(6):317\u2013325","journal-title":"Cancer Gene Ther"},{"issue":"24","key":"3092_CR218","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.3748\/wjg.14.3819","volume":"14","author":"M Sieben","year":"2008","unstructured":"Sieben M, Herzer K, Zeidler M, Heinrichs V, Leuchs B, Schuler M et al (2008) Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein. World J Gastroenterol 14(24):3819","journal-title":"World J Gastroenterol"},{"issue":"11","key":"3092_CR219","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/gt.2013.28","volume":"20","author":"J Lampe","year":"2013","unstructured":"Lampe J, Bossow S, Weiland T, Smirnow I, Lehmann R, Neubert W et al (2013) An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis. Gene Ther 20(11):1033\u20131041","journal-title":"Gene Ther"},{"issue":"7","key":"3092_CR220","doi-asserted-by":"publisher","first-page":"667","DOI":"10.7150\/thno.10438","volume":"5","author":"I Almstatter","year":"2015","unstructured":"Almstatter I, Mykhaylyk O, Settles M, Altomonte J, Aichler M, Walch A et al (2015) Characterization of magnetic viral complexes for targeted delivery in oncology. Theranostics 5(7):667\u2013685","journal-title":"Theranostics"},{"issue":"6","key":"3092_CR221","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1002\/hep.22546","volume":"48","author":"J Altomonte","year":"2008","unstructured":"Altomonte J, Braren R, Schulz S, Marozin S, Rummeny EJ, Schmid RM et al (2008) Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology 48(6):1864\u20131873","journal-title":"Hepatology"},{"issue":"12","key":"3092_CR222","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1166\/jbn.2014.2051","volume":"10","author":"C Lai","year":"2014","unstructured":"Lai C, Yu X, Zhuo H, Zhou N, Xie Y, He J et al (2014) Anti-tumor immune response of folate-conjugated chitosan nanoparticles containing the IP-10 gene in mice with hepatocellular carcinoma. J Biomed Nanotechnol 10(12):3576\u20133589","journal-title":"J Biomed Nanotechnol"},{"issue":"10","key":"3092_CR223","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1089\/hum.2009.135","volume":"20","author":"RJ Prestwich","year":"2009","unstructured":"Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA et al (2009) The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther 20(10):1119\u20131132","journal-title":"Hum Gene Ther"},{"issue":"3","key":"3092_CR224","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3892\/ijmm.2012.1027","volume":"30","author":"H He","year":"2012","unstructured":"He H, Fan P, Yin T, Chen Q, Shi H, Liu S et al (2012) Local delivery of recombinant adenovirus expressing hepatitis B virus X protein and interleukin-12 results in antitumor effects via inhibition of hepatoma cell growth and intervention of tumor microenvironment. Int J Mol Med 30(3):599\u2013605","journal-title":"Int J Mol Med"},{"issue":"9","key":"3092_CR225","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1084\/jem.188.9.1641","volume":"188","author":"P Romero","year":"1998","unstructured":"Romero P, Dunbar PR, Valmori D, Ml Pittet, Ogg GS, Rimoldi D et al (1998) Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 188(9):1641\u20131650","journal-title":"J Exp Med"},{"issue":"5","key":"3092_CR226","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00109-003-0430-2","volume":"81","author":"H Dong","year":"2003","unstructured":"Dong H, Chen L (2003) B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med 81(5):281\u2013287","journal-title":"J Mol Med"},{"issue":"12","key":"3092_CR227","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, Chen L (1999) B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5(12):1365\u20131369","journal-title":"Nat Med"},{"issue":"1","key":"3092_CR228","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00262-011-1094-3","volume":"61","author":"J Chen","year":"2012","unstructured":"Chen J, Li G, Meng H, Fan Y, Song Y, Wang S et al (2012) Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas. Cancer Immunol Immunother 61(1):101\u2013108","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"3092_CR229","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/1078-0432.CCR-08-1608","volume":"15","author":"Q Gao","year":"2009","unstructured":"Gao Q, Wang X-Y, Qiu S-J, Yamato I, Sho M, Nakajima Y et al (2009) Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 15(3):971\u2013979","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3092_CR230","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.molimm.2007.07.038","volume":"45","author":"G Peng","year":"2008","unstructured":"Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z (2008) PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 45(4):963\u2013970","journal-title":"Mol Immunol"},{"issue":"17","key":"3092_CR231","doi-asserted-by":"publisher","first-page":"9249","DOI":"10.1128\/JVI.00409-07","volume":"81","author":"L Golden-Mason","year":"2007","unstructured":"Golden-Mason L, Palmer B, Klarquist J, Mengshol JA, Castelblanco N, Rosen HR (2007) Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol 81(17):9249\u20139258","journal-title":"J Virol"},{"issue":"2","key":"3092_CR232","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrc2051","volume":"7","author":"I Melero","year":"2007","unstructured":"Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L (2007) Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 7(2):95\u2013106","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3092_CR233","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","volume":"59","author":"B Sangro","year":"2013","unstructured":"Sangro B, Gomez-Martin C, de la Mata M, I\u00f1arrairaegui M, Garralda E, Barrera P et al (2013) A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59(1):81\u201388","journal-title":"J Hepatol"},{"issue":"3","key":"3092_CR234","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/hep.23054","volume":"50","author":"B Hoechst","year":"2009","unstructured":"Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H et al (2009) Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50(3):799\u2013807","journal-title":"Hepatology"},{"issue":"7","key":"3092_CR235","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1053\/j.gastro.2007.03.102","volume":"132","author":"J Fu","year":"2007","unstructured":"Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B et al (2007) Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132(7):2328\u20132339","journal-title":"Gastroenterology"},{"issue":"18","key":"3092_CR236","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1200\/JCO.2006.09.4565","volume":"25","author":"Q Gao","year":"2007","unstructured":"Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS et al (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25(18):2586\u20132593","journal-title":"J Clin Oncol"},{"issue":"5","key":"3092_CR237","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/hep.27665","volume":"61","author":"Y Chen","year":"2015","unstructured":"Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y et al (2015) CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology 61(5):1591\u20131602","journal-title":"Hepatology"},{"issue":"3","key":"3092_CR238","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2217\/imt.15.126","volume":"8","author":"T Hato","year":"2016","unstructured":"Hato T, Zhu AX, Duda DG (2016) Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Immunotherapy 8(3):299\u2013313","journal-title":"Immunotherapy"},{"issue":"1","key":"3092_CR239","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3892\/ijo.2014.2737","volume":"46","author":"Y Sawada","year":"2015","unstructured":"Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, Nakatsura T (2015) Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int J Oncol 46(1):28\u201336","journal-title":"Int J Oncol"},{"issue":"4","key":"3092_CR240","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/hep.26761","volume":"59","author":"JD Yang","year":"2014","unstructured":"Yang JD, Abdelmalek MF, Pang H, Guy CD, Smith AD, Diehl AM, Suzuki A (2014) Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 59(4):1406\u20131414","journal-title":"Hepatology"},{"issue":"25","key":"3092_CR241","doi-asserted-by":"publisher","first-page":"7613","DOI":"10.3748\/wjg.v21.i25.7613","volume":"21","author":"CW Brady","year":"2015","unstructured":"Brady CW (2015) Liver disease in menopause. World J Gastroenterol 21(25):7613\u20137620","journal-title":"World J Gastroenterol"},{"key":"3092_CR242","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1479-5876-12-93","volume":"12","author":"L Shi","year":"2014","unstructured":"Shi L, Feng Y, Lin H, Ma R, Cai X (2014) Role of estrogen in hepatocellular carcinoma: is inflammation the key? J Transl Med 12:93","journal-title":"J Transl Med"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-017-3092-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-017-3092-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-017-3092-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:56:27Z","timestamp":1750294587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-017-3092-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,7]]},"references-count":242,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["3092"],"URL":"https:\/\/doi.org\/10.1007\/s11010-017-3092-z","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,7]]},"assertion":[{"value":"19 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no other relevant affiliations or financial involvement with any organization or entity with the financial interest or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}